Teleflex Incorporated
NYSE•TFX
CEO: Mr. Liam J. Kelly
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1980-03-17
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Contact Information
550 East Swedesford Road, Suite 400, Wayne, PA, 19087-1603, United States
610-225-6800
Market Cap
$5.25B
P/E (TTM)
-16.0
27.9
Dividend Yield
1.1%
52W High
$188.87
52W Low
$102.58
52W Range
Rank43Top 38.2%
4.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$913.02M+19.45%
4-Quarter Trend
EPS
-$9.24-488.23%
4-Quarter Trend
FCF
$77.69M-62.97%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Growth Strong Nine months net revenues hit $2.39B USD, increasing 6.3% over prior period, driven by VI Business.
VI Acquisition Financing Acquisition contributed $101.8M revenue in nine months, financed via $1.14B in new borrowings.
Cash Position Stable Total cash, cash equivalents, and restricted cash ended at $381.3M USD as of September 28, 2025.
Operating Cash Flow Dip Operating cash flow from continuing operations dropped $246.6M USD for nine months compared to prior year.
Risk Factors
Goodwill Impairment Hit Recognized $403.9M goodwill impairment charge for IU reporting unit during the third quarter of 2025.
Asset Impairment Recorded Recorded $100.0M impairment charge for Titan SGS assets due to revised lower sales forecasts.
Restructuring Charges High Incurred $117.6M restructuring charges in Q3 2025, including $100.0M asset impairment charge.
Tariff Impact Monitoring Enacted U.S. tariffs negatively impacted gross margins and cash flows for both three and nine months.
Outlook
Corporate Separation Plan Actively advancing potential sale of NewCo following announced strategic separation decision in February 2025.
VI Integration Restructuring New VI Business integration plan estimates $36M to $44M total restructuring charges through expected completion 2028.
Future Savings Expected VI Business integration plan expects to begin realizing annual pre-tax savings of $24M to $30M in 2026.
Peer Comparison
Revenue (TTM)
OSCR$11.29B
$4.97B
BRKR$3.44B
Gross Margin (Latest Quarter)
PTCT92.5%
ALKS86.9%
TGTX86.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| BRKR | $7.34B | -370.7 | -1.0% | 31.2% |
| KRYS | $6.44B | 32.3 | 19.4% | 0.1% |
| STVN | $6.26B | 38.8 | 9.9% | 18.8% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.7%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 28, 2025|Filed: Nov 6, 2025|Revenue: $913.02M+19.4%|EPS: $-9.24-488.2%MissForm 10-Q - Q2 2025
Period End: Jun 29, 2025|Filed: Jul 31, 2025|Revenue: $780.89M+4.2%|EPS: $2.77+62.9%MissForm 10-Q - Q1 2025
Period End: Mar 30, 2025|Filed: May 1, 2025|Revenue: $700.67M-5.0%|EPS: $2.08+550.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 28, 2025|Revenue: $3.05B+2.4%|EPS: $1.49-80.3%MissForm 10-Q - Q3 2024
Period End: Sep 29, 2024|Filed: Oct 31, 2024|Revenue: $764.38M+2.4%|EPS: $2.38-18.5%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 2, 2024|Revenue: $749.69M+0.9%|EPS: $1.70-28.3%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 3, 2024|Revenue: $737.85M+3.8%|EPS: $0.32-80.4%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 23, 2024|Revenue: $2.97B+6.6%|EPS: $7.58-2.1%Beat